ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ABCL / forecast
ARQT (54) LQDA (36) TNGX (45) INDV (51) ⌘ Pro Terminal →

AbCellera Biologics Inc. (ABCL) 12-Month Stock Forecast & Price Target Cone

$11.12 -9.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.91

AbCellera Biologics Inc. (ABCL) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.97B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABCL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, AbCellera Biologics Inc. (NASDAQ: ABCL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.12 (-9.37% 1D, market cap $3.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, ABCL ranks #381 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABCL compare to ARQT and LQDA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABCL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.5%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and LQDA (Liquidia Corporation) posts a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABCL?
▼

Per ABCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703057), AbCellera Biologics Inc. generated $75.1M in revenue (+160.6% YoY), -$146.4M in net income, and -$174.1M in free cash flow against $1.36B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.91 (-1.88%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (8)Whales (12)SEC (14)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$16 Bull$10 Base$8 Bear
📬 FREE ABCL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABCL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY ABCL SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 6.60 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
52
Grade C-$12.64-5.6% Next Q
Q2 (-2Q)
49
Grade D$11.93+1.3% Next Q
Q3 (-1Q)
47
Grade D$12.08-7.9% Next Q
Current
44
Grade D$11.12-6.5% Hist 90D α
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABCL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABCL currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.31) and Max Pain ($11.68) forces dealer call-delta covering toward $15.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABCL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABCL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ABCL Position Size: $10,000

Shares at $11.12: 899.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $8.13
$7,311
$-2,689 (-26.9%)
12M Consensus BaseTarget $10.42
$9,371
$-629 (-6.3%)
12M Bull Case BreakoutTarget $15.77
$14,182
+$4,182 (+41.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1569%B
JP MorganUS Large-Cap ResearchSELL$958%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABCL)

  • ✓Walkthrough of ABCL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ABCL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +142.27%▲ ASCENDING CHANNEL
2026-11-03O $13.08H $13.08L $11.12C $11.12VOL 3.88M
RES: $17.22SUP: $6.45SMA50: $12.31SMA200: $6.89
$15.82$12.52$9.22$5.92$2.63RES $17.22SUP $6.45$11.122026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABCL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABCL Butterfly Map → + Track ABCL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +160.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABCL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABCL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABCL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABCL)

Health Care Rank #381 of 1016 ⚔️ ARQT vs ABCL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABCL vs. ARQT, LQDA, TNGX, INDV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AbCellera Biologics Inc. (ABCL) ranks #381 by composite RQD confidence (44/100, grade D) and #183 by equity capitalization ($3.97B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. ARQT currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ABCL at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABCL ACTIVE
AbCellera Biologics Inc.
D 44/100 — — -20.5% -9.37% $3.97B Benchmark Subject
ARQT
Arcutis Biotherapeutics Inc.
D+ 54/100 — 90.2% -3.0% -2.53% $4.03B /arqt-vs-abcl →
LQDA
Liquidia Corporation
D- 36/100 — — -12.6% -7.12% $4.03B /lqda-vs-abcl →
TNGX
Tango Therapeutics Inc.
D 45/100 — — -28.9% -4.22% $3.83B /tngx-vs-abcl →
INDV
Indivior Pharmaceuticals Inc.
D 51/100 19.8x 80.2% 62.2% +0.34% $4.17B /indv-vs-abcl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001703057 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AbCellera Biologics Inc. (ABCL) reported GAAP revenue of $75.1M (+160.6% vs. FY2024 revenue of $28.8M , and +97.6% cumulative change since FY2023) , GAAP net income of -$146.4M, operating cash flow of -$131.3M, and free cash flow of -$174.1M (+6.9% YoY). On the balance sheet, ABCL closed FY2025 with $1.36B in total assets against $0 in total debt (Altman Z-Score: 6.60, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $75.1M -$146.4M -$131.3M -$174.1M $1.36B —
FY2024 (FY) 2024-12-31 $28.8M -$162.9M -$108.6M -$187.0M $1.36B —
FY2023 (FY) 2023-12-31 $38.0M -$146.4M -$43.9M -$43.9M — —

3. ABCL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AbCellera Biologics Inc. (NASDAQ: ABCL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.12 (-9.37% 1D, market cap $3.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, ABCL ranks #381 in composite RQD confidence.

How does ABCL compare to ARQT and LQDA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABCL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.5%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and LQDA (Liquidia Corporation) posts a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABCL?

Per ABCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703057), AbCellera Biologics Inc. generated $75.1M in revenue (+160.6% YoY), -$146.4M in net income, and -$174.1M in free cash flow against $1.36B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABCL trading relative to its 50-day, 200-day, and 52-week technical levels?

ABCL last traded at $11.12 (-9.37% on volume of 3,037,180 shares), positioning the stock -9.67% below its 50-day simple moving average ($12.31) and +61.39% above its 200-day simple moving average ($6.89). Across its 52-week range of $2.74 to $15.02, ABCL sits at the 68.2% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.73 to $12.51).

Direct Sub-Reports: ABCL RQD Cockpit ABCL 12M Forecast ABCL Earnings & Move ABCL Dividends & DRIP ABCL Insiders & 13F ABCL Whale Options ABCL Profit Sankey ABCL News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

ABCL — AbCellera Biologics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AbCellera Biologics Inc. (ABCL) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $11.12 (-9.37% 1D, market capitalization $3.97B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -20.5%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -4.11%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 6.60, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AbCellera Biologics Inc. (ABCL) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. Gross margin is 0% per the market data, and operating margin is -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AbCellera Biologics Inc. (ABCL) reported $75.1M in annual revenue (up from $28.8M in FY2024, +160.6% YoY) and -$146.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($38.0M revenue, -$146.4M net income) through FY2025, ABCL scaled operating cash flow to -$131.3M and free cash flow to -$174.1M, backed by $1.36B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.11% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $2.74 – $15.02 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE, butterfly_links is empty, and proprietary_signals is empty. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are — The one ripple a prospective investor should monitor is the October 13, 2026 lock-up expiry noted in the news feed, which could add supply to the float.

  • Key Question #1: Can ABCL sustain or expand its -60.0% operating margin and -20.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $75.1M and free cash flow of -$174.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ABCL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ABCL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AbCellera Biologics Inc. (ABCL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABCL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABCL Bull vs. Bear Conversation Board — What's Your Call at $11.12?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABCL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABCL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $14.60 (+19.0%)
📌 Pinned Debate

Positive ABCL635 Phase 2 read-through and a UBS Buy initiation at an $18 target point to upside from the $12.27 price.

Don't sleep on ABCL's setup in Health Care. Positive ABCL635 Phase 2 read-through and a UBS Buy initiation at an $18 target point to upside from the $12.27 price.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (44/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $10.06 (-18.0%)
Spot @ $12.27

Negative ROIC of -20.5% and FCF of -$174.1M in FY 2025 show a cash-burning business priced at a $4.24B market cap.

Fading this rally in ABCL at $12.27. Negative ROIC of -20.5% and FCF of -$174.1M in FY 2025 show a cash-burning business priced at a $4.24B market cap.. With a beta of 1.0 and the stock sitting at $12.27 (52-wk range $2.25–$15.02), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%